Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some safety-related statements (e.g., dizziness/somnolence, coordination/unsteadiness-like effects, blurred vision, and warnings about concomitant CNS depressants and respiratory depression) are generally consistent with the provided label excerpts, but many other claims are unsupported or not addressed in the supplied prescribing information, particularly those about antidepressant co-prescribing patterns, specific antidepressant classes as causes of drowsiness, titration practices, and detailed interaction/clinical management advice.
Category Scores
Accurate Statements
Pregabalin can cause sedation.
5.5 Dizziness and Somnolence: 'may cause dizziness and somnolence' and 6.1 most common adverse events include 'somnolence'.
Pregabalin can cause slowed reaction time.
5.5: dizziness/somnolence may impair tasks such as 'driving or operating machinery'. (No exact phrase 'slowed reaction time'.)
Pregabalin can cause dizziness.
5.5: 'may cause dizziness'.
Pregabalin can cause trouble with coordination.
5.5 indicates CNS effects impairing tasks like driving; label excerpt does not explicitly state 'coordination', but dizziness/somnolence would be consistent. (No explicit coordination wording.)
Some tricyclic antidepressants (TCAs) commonly cause drowsiness.
Mirtazapine commonly causes drowsiness.
Combining pregabalin with an antidepressant that causes drowsiness may cause increased sleepiness or grogginess.
5.5: concomitant use with other CNS depressants may exacerbate dizziness/somnolence; 5.4 respiratory depression section also links to CNS depressants and monitoring for 'sedation'.
Combining pregabalin with an antidepressant that causes drowsiness may cause dizziness or lightheadedness.
5.5: pregabalin-related dizziness/somnolence; concomitant use with CNS depressants may exacerbate these effects.
Combining pregabalin with an antidepressant that causes drowsiness may cause unsteadiness when walking.
Not explicitly stated; however label includes dizziness/somnolence and impaired ability to perform tasks (5.5).
Combining pregabalin with an antidepressant that causes drowsiness may cause slowed mental function.
Not explicitly stated; label provides dizziness/somnolence and impaired tasks (5.5) but does not mention mental slowness.
When pregabalin is combined with antidepressants, excessive sleepiness or fatigue may occur.
6.1: most common adverse events include 'somnolence' and 'fatigue'; 5.5: concomitant CNS depressants may exacerbate dizziness/somnolence.
When pregabalin is combined with antidepressants, dizziness or balance problems may occur.
5.5: dizziness; no explicit 'balance problems', but dizziness/somnolence effects are directly described.
When pregabalin is combined with antidepressants, confusion or trouble concentrating may occur.
When pregabalin is combined with antidepressants, blurred vision may occur.
5.10 Ophthalmological Effects: 'blurred vision' reported; 6.1 includes 'blurred vision' as common adverse event.
When pregabalin is combined with antidepressants, clumsiness or falls may occur.
The risk of clumsiness or falls is higher if the patient already feels unsteady.
In many cases, pregabalin does not have a classic, direct drug–drug interaction with SSRIs such as sertraline.
7: 'pharmacokinetics are unlikely to be affected by other agents through metabolic interactions'; no specific SSRI interaction described in label excerpts.
In many cases, pregabalin does not have a classic, direct drug–drug interaction with SSRIs such as escitalopram.
7: general statement about unlikely metabolic/protein binding displacement effects; no specific escitalopram mention in provided excerpts.
In many cases, pregabalin does not have a classic, direct drug–drug interaction with SNRIs such as venlafaxine.
7: general pharmacokinetic interaction statement; no specific venlafaxine mention in provided excerpts.
In many cases, pregabalin does not have a classic, direct drug–drug interaction with SNRIs such as duloxetine.
7: general pharmacokinetic interaction statement; no specific duloxetine mention in provided excerpts.
With SSRIs or SNRIs, the main overlap when combined with pregabalin is side effects, especially sleepiness, dizziness, and coordination problems.
5.5 and 6.1 support overlap of sedation/dizziness as effects; label excerpts do not specifically mention SSRIs/SNRIs or 'coordination problems'.
The interaction risk with MAOIs or other higher-risk antidepressants depends on the specific drug and the overall regimen.
Not supported explicitly by provided excerpts (7 provides general PK reasoning and lack of systematic evaluation; no MAOI specifics).
With CNS depressants (including opioids), when co-prescribed, monitor patients for symptoms of respiratory depression and sedation, and consider initiating at a low dose.
5.4 Respiratory Depression: explicit monitoring and low-dose initiation guidance.
Avoiding alcohol is a safety step when using pregabalin with antidepressants.
Other sedating medicines can intensify drowsiness when used with pregabalin.
5.5: concomitant use with other CNS depressants may exacerbate dizziness and somnolence.
Avoiding driving or operating machinery until you know how the combination affects you is a safety step.
5.5: dizziness/somnolence may impair ability to perform tasks such as driving or operating machinery.
Suddenly changing doses of pregabalin or the antidepressant without medical advice is not recommended.
5.6: taper pregabalin gradually over a minimum of 1 week; no label excerpt about antidepressant dose changes.
Contact a clinician promptly if breathing problems occur when using pregabalin with antidepressants.
5.4: respiratory depression risk with CNS depressants; monitoring for symptoms of respiratory depression and sedation. (No exact 'contact clinician promptly' phrasing.)
Contact a clinician promptly if signs of an allergic reaction (swelling, hives, rash, trouble breathing) occur when using pregabalin with antidepressants.
4 contraindications/5.1 angioedema symptoms and 5.2 hypersensitivity reactions include hives/rash/dyspnea/wheezing; discontinue immediately in those symptoms.
Contact a clinician promptly if worsening depression or new suicidal thoughts occur when using pregabalin with antidepressants.
5.3 Suicidal Behavior and Ideation: monitor patients for emergence/worsening depression and suicidal thoughts/behavior.
Unsupported Statements
Pregabalin can cause trouble with coordination.
Provided label excerpts do not explicitly mention coordination.
Pregabalin is sometimes prescribed alongside antidepressants when treating conditions such as anxiety disorders, neuropathic pain, or fibromyalgia with mood symptoms.
The provided label excerpts do not discuss anxiety disorders, fibromyalgia adjunctive use for mood symptoms, or prescribing patterns with antidepressants.
Taking pregabalin and antidepressants together is common in practice.
No information in provided label excerpts about real-world prescribing frequency.
The decision to take pregabalin with antidepressants depends on which antidepressant is used and on personal risk factors.
No antidepressant-specific guidance or 'risk factors' framework provided in excerpts.
Pairing pregabalin with antidepressants that also cause drowsiness can increase side-effect burden.
Label supports CNS depressants may exacerbate dizziness/somnolence, but antidepressant-specific 'also cause drowsiness' and 'side-effect burden' framing is not explicitly supported.
The biggest practical issue with combining pregabalin and an antidepressant is additive sedation when an antidepressant already makes you sleepy.
Label does not characterize the 'biggest practical issue' or antidepressant-specific additive sedation.
Some tricyclic antidepressants (TCAs) commonly cause drowsiness.
Not addressed in provided pregabalin label excerpts.
Mirtazapine commonly causes drowsiness.
Not addressed in provided pregabalin label excerpts.
Combining pregabalin with an antidepressant that causes drowsiness may cause unsteadiness when walking.
No explicit unsteadiness/walking/balance adverse effects described in provided excerpts.
Combining pregabalin with an antidepressant that causes drowsiness may cause slowed mental function.
No explicit claim in provided label excerpts about cognitive slowing.
When pregabalin is combined with antidepressants, confusion or trouble concentrating may occur.
Not stated in provided label excerpts.
When pregabalin is combined with antidepressants, clumsiness or falls may occur.
Not stated in provided label excerpts.
The risk of clumsiness or falls is higher if the patient already feels unsteady.
Not stated in provided label excerpts.
Clinicians often start with lower doses when using pregabalin in combination and adjust gradually to reduce these effects.
Label excerpt supports initiating pregabalin low dose when co-prescribing with CNS depressants (not 'clinicians often' or antidepressant context).
When starting both pregabalin and an antidepressant, following the titration schedule exactly is a safety step.
Label discusses tapering pregabalin on discontinuation and low-dose initiation with CNS depressants; it does not provide combined titration schedule instruction or 'exactly' language.
Pregabalin is often increased gradually.
Label provides initiation and titration guidance for indications, but does not support the generalized claim in the context of antidepressant combination.
Avoiding alcohol is a safety step when using pregabalin with antidepressants.
No alcohol-specific counseling in provided label excerpts.
Contact a clinician promptly if severe sedation that affects daily functioning occurs when using pregabalin with antidepressants.
Label advises monitoring for sedation and respiratory depression when co-prescribing CNS depressants, but does not specify 'contact a clinician promptly' or 'daily functioning' phrasing.
Contact a clinician promptly if new severe dizziness, fainting, or falls occur when using pregabalin with antidepressants.
Provided label excerpts mention dizziness/somnolence and monitoring, but do not mention fainting or falls or provide this exact counseling.
Contradictions
Low
AI Statement
Suddenly changing doses of pregabalin or the antidepressant without medical advice is not recommended.
Label Reference
5.6 requires tapering pregabalin gradually rather than abrupt discontinuation; does not directly contradict. (No direct contradiction to label provided.)
Important Omissions
FDA-labeled indications and dosing regimens were not addressed relative to the antidepressant-combination claims (e.g., label indications: diabetic peripheral neuropathy and postherpetic neuralgia; ER dosing once daily after an evening meal).
Importance:
Moderate
No mention of label contraindication/hypersensitivity and specific discontinuation guidance for angioedema/hypersensitivity beyond general 'contact clinician' statements.
Importance:
Moderate
No label-anchored guidance on renal impairment dosing/avoidance (not recommended for CLcr < 30 mL/min or hemodialysis).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some statements align with label safety warnings (dizziness/somnolence, blurred vision, suicidal behavior monitoring, hypersensitivity/angioedema symptoms, and monitoring with CNS depressants). However, multiple unsupported or overly specific claims about antidepressant classes, combination patterns, and adverse outcomes (e.g., confusion, falls/clumsiness, cognitive slowing) are not substantiated by the provided label excerpts, reducing audit reliability.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Many antidepressant-specific and practice-pattern claims are not supported by the provided pregabalin extended-release label excerpts.
Suggested Improvement
Restrict combination/interaction counseling to label-supported concepts: dizziness/somnolence effects (5.5/6.1), blurred vision (5.10/6.1), hypersensitivity/angioedema discontinuation symptoms (5.1/5.2), suicidal behavior monitoring (5.3), and monitoring/low-dose considerations when co-prescribing with CNS depressants (5.4/7). Remove or qualify antidepressant-class-specific assertions and unlabelled adverse-effect claims (confusion, falls/clumsiness, cognitive slowing, fainting).